Nexstim Plc to host Webinars to Present a Business Update and Information about the Rights Issue 2020 – GlobeNewswire

Company Announcement, Helsinki, 11 May 2020 at 4.30 pm (EEST)

Nexstim Plc to host Webinars to Present a Business Update and Information about the Rights Issue 2020

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the Company will hold two live webinars for analysts, investors and media on Friday 15 May 2020.

The first live webinar will be in Finnish and it takes place at 10 am EEST. The second live webinar will be in English at 3 pm EEST.

The webinar will be hosted by Chief Executive Officer Mikko Karvinen who will present companys business update and information about the rights issue 2020 followed by a Q&A session.

Webinar details:

To attend the webinars, please register via the links below. Registered participants will receive more information to their e-mail.

Live Webinar in Finnish on 15 May 2020 at 10am (EEST): Register here >>>

Live Webinar in English on 15 May 2020 at 3pm (EEST): Register here >>>

Further information is available on the website http://www.nexstim.com, or by contacting:

Mikko Karvinen, CEO+358 50326 4101 mikko.karvinen@nexstim.com

Sisu Partners Oy (Certified Adviser)Jussi Majamaa+ 358 40 842 4479jussi.majamaa@sisupartners.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus technology is used in Nexstims proprietary Navigated Brain Therapy (NBT) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visitwww.nexstim.com

Read the rest here:

Nexstim Plc to host Webinars to Present a Business Update and Information about the Rights Issue 2020 - GlobeNewswire

Related Post

Comments are closed.